{
    "clinical_study": {
        "@rank": "151452", 
        "arm_group": [
            {
                "arm_group_label": "Ertuglifozin 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Participants will receive 1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet per day. Participants requiring glycemic rescue during the 26-week initial treatment period (Phase A) will receive open-label glimepiride. This rescue will continue through the 78-week, double-blind, extension period (Phase B). If not rescued during Phase A, participants will receive placebo to glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) during Phase B. All participants will also receive metformin at a dose >=1500 mg/day in Phase A and B."
            }, 
            {
                "arm_group_label": "Ertugliflozin 15 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Participants will receive 1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet per day. Participants requiring glycemic rescue during the 26-week initial treatment period (Phase A) will receive open-label glimepiride. This rescue will continue through the 78-week, double-blind, extension period (Phase B). If not rescued during Phase A, participants will receive placebo to glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) during Phase B. All participants will also receive metformin at a dose >=1500 mg/day in Phase A and B."
            }, 
            {
                "arm_group_label": "Placebo to Ertugliflozin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to ertuglioflozin, orally once daily from Day 1 to Week 104. Participants will receive 1 placebo ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet per day. Participants requiring glycemic rescue during the 26-week initial treatment period (Phase A) will receive open-label glimepiride. This rescue will continue through the 78-week, double-blind, extension period (Phase B). If not rescued during Phase A, participants will receive blinded glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) during Phase B. All participants will also receive metformin at a dose >=1500 mg/day in Phase A and B."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes\n      mellitus and inadequate glycemic control on metformin monotherapy. The primary study\n      hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c)\n      for ertugliflozin is greater than that for placebo."
        }, 
        "brief_title": "A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The trial includes a 13-15 week run-in period prior to randomization, and a 26-week,\n      double-blind, placebo-controlled treatment period (Phase A) followed by a 78-week\n      double-blind, extension period (Phase B)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of T2DM in accordance to American Diabetes Association guidelines\n\n          -  Participants must be receiving metformin monotherapy for less than 8 weeks prior to\n             study participation or require change in their diabetes regimen to remain eligible to\n             participate in the trial (including discontinuing anti-hyperglycemic agent [AHA]\n             therapy) and must have a hemoglobin A1c of 7.0 to 10.5% (53-91 mmol/mol) after at\n             least 8 weeks on a regimen of metformin monotherapy\n\n        Exclusion Criteria: - History of myocardial infarction, unstable angina, arterial\n        revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA)\n        functional class III-IV heart failure within 3 months of study participation\n\n          -  A clinically significant electrocardiogram abnormality\n\n          -  A history of malignancy \u22645 years prior to study participation, except for adequately\n             treated basal or squamous cell skin cancer or in situ cervical cancer\n\n          -  A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2\n             (SGLT2) inhibitor or glimepiride\n\n          -  On a blood pressure or lipid altering medication that have not been on a stable dose\n             for at least 4 weeks prior to study participation\n\n          -  A surgical procedure within 6 weeks prior to study participation or planned major\n             surgery during the trial\n\n          -  Donation of blood or blood products within 6 weeks of study participation or plans to\n             donate blood or blood products at any time during the trial\n\n          -  Pregnant or breast-feeding, or is expecting to conceive during the trial, including\n             14 days following the last dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033889", 
            "org_study_id": "8835-007", 
            "secondary_id": [
                "2013-003290-95", 
                "B1521017"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Ertuglifozin 5 mg", 
                "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104.", 
                "intervention_name": "Ertugliflozin 5 mg", 
                "intervention_type": "Drug", 
                "other_name": "MK-8835"
            }, 
            {
                "arm_group_label": "Ertugliflozin 15 mg", 
                "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104.", 
                "intervention_name": "Ertugliflozin 15 mg", 
                "intervention_type": "Drug", 
                "other_name": "MK-8835"
            }, 
            {
                "arm_group_label": "Placebo to Ertugliflozin", 
                "description": "Placebo to ertuglioflozin, orally once daily from Day 1 to Week 104.", 
                "intervention_name": "Placebo to Ertugliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertuglifozin 5 mg", 
                    "Ertugliflozin 15 mg", 
                    "Placebo to Ertugliflozin"
                ], 
                "description": "Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period.  Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of blinded glimepiride is at the discretion of the investigator.", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Other", 
                "other_name": [
                    "Amaryl", 
                    "GLIMPID", 
                    "GLIMY"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertuglifozin 5 mg", 
                    "Ertugliflozin 15 mg"
                ], 
                "description": "Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.", 
                "intervention_name": "Placebo to Glimepiride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertuglifozin 5 mg", 
                    "Ertugliflozin 15 mg", 
                    "Placebo to Ertugliflozin"
                ], 
                "description": "Basal insulin will be used for participants requiring rescue therapy in Phase B. Dosing and titration of basal insulin is at the discretion of the Investigator.", 
                "intervention_name": "Basal Insulin", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Insulin glargine", 
                    "Insulin detemir", 
                    "NPH insulin", 
                    "Degludec"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertuglifozin 5 mg", 
                    "Ertugliflozin 15 mg", 
                    "Placebo to Ertugliflozin"
                ], 
                "description": "Metformin >=1500 mg/day, orally, once a day", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Glucophage XR", 
                    "Carbophage SR", 
                    "Riomet", 
                    "Fortamet", 
                    "Glumetza", 
                    "Obimet", 
                    "Gluformin", 
                    "Dianben", 
                    "Diabex", 
                    "Diaformin", 
                    "Siofor", 
                    "Metfogamma"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Glargine", 
                "Insulin", 
                "Insulin, NPH", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Riverside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92506"
                    }, 
                    "name": "Call for Information (Investigational Site 1126)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tustin", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92780"
                    }, 
                    "name": "Call for Information (Investigational Site 1132)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91307"
                    }, 
                    "name": "Call for Information (Investigational Site 1130)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33012"
                    }, 
                    "name": "Call for Information (Investigational Site 1134)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31419"
                    }, 
                    "name": "Call for Information (Investigational Site 1112)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31406"
                    }, 
                    "name": "Call for Information (Investigational Site 1125)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27408"
                    }, 
                    "name": "Call for Information (Investigational Site 1107)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fargo", 
                        "country": "United States", 
                        "state": "North Dakota", 
                        "zip": "58103"
                    }, 
                    "name": "Call for Information (Investigational Site 1131)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Darby", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19023"
                    }, 
                    "name": "Call for Information (Investigational Site 1123)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "Call for Information (Investigational Site 1129)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "Call for Information (Investigational Site 1117)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Corpus Christi", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78404"
                    }, 
                    "name": "Call for Information (Investigational Site 1115)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Call for Information (Investigational Site 1138)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77801"
                    }, 
                    "name": "Call for Information (Investigational Site 1193)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }, 
                    "name": "Call for Information (Investigational Site 1121)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schertz", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78154"
                    }, 
                    "name": "Call for Information (Investigational Site 1111)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spring", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77379"
                    }, 
                    "name": "Call for Information (Investigational Site 1109)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Walla Walla", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99362"
                    }, 
                    "name": "Call for Information (Investigational Site 1122)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Hemoglobin A1c", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of Participants Experiencing An Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 106"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 104"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Fasting Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Body Weight at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of participants with a HbA1c of <7% (53 mmol/mol) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Change from Baseline in Systolic Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Diastolic Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Bone Mineral Density at Week 26", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Bone Mineral Density at Week 52", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "measure": "Change from Baseline in Bone Mineral Density at Week 104", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 104"
            }, 
            {
                "measure": "Number of participants with HbA1c <=6.5% (48 mmol/mol) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Number of participants requiring glycemic rescue therapy up to Week 26", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 26"
            }, 
            {
                "measure": "Time to glycemic rescue therapy up to Week 26", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 26"
            }, 
            {
                "measure": "Change from baseline in bone biomarkers at Week 26", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from baseline in bone biomarkers at Week 52", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "measure": "Change from baseline in bone biomarkers at Week 104", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 104"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}